Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization |
(ii) EIN |
(iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) |
(iv) Is the organization in col. (i) listed in your governing document? |
(v) Did you notify the organization in col. (i) of your support? |
(vi) Is the organization in col. (i) organized in the U.S.? |
(vii) Amount of support? |
|||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 16,724,026 | 14,878,740 | 13,577,309 | 3,460,179 | 13,617,695 | 62,257,949 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3.. | 16,724,026 | 14,878,740 | 13,577,309 | 3,460,179 | 13,617,695 | 62,257,949 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 590,659 | |||||
| 6 | Public Support. Subtract line 5 from line 4. | 61,667,290 | |||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 16,724,026 | 14,878,740 | 13,577,309 | 3,460,179 | 13,617,695 | 62,257,949 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 1,082,178 | 1,100,500 | -11,167 | 131,265 | 368,774 | 2,671,550 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets.. | 592,364 | 501,961 | 197,390 | 645,812 | 1,937,527 | |
| 11 | Total support (Add lines 7 through 10). | 66,867,026 | |||||






| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public Support (Subtract line 7c from line 6.) | ||||||
| Calendar year (or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) | ||||||
| 13 | Total support (Add lines 9, 10c, 11 and 12.). | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| FORM 990, PART VI, SECTION A, LINE 2 | FRANKLIN SALISBURY, PRESIDENT AND CEO, AND SUJUAN BA, COO/CFO/SECRETARY ARE HUSBAND AND WIFE. SREEKUMAR RAGHAVAKIMAL, SENIOR VP OF DEVELOPMENT AND PADMAKUMAR RAGHAVAKAIMAL, BOARD DIRECTOR, ARE BROTHERS. | |
| FORM 990, PART VI, SECTION B, LINE 10B | THE LOCAL CHAPTER HAD LITTLE ACTIVITIES AND A POLICY IS BEING DRAFTED. | |
| FORM 990, PART VI, SECTION B, LINE 11 | THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE 990: 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CONTROLLER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBERS' COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFICIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILING DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. | |
| FORM 990, PART VI, SECTION B, LINE 12C | EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE CORPORATION HAS, OR MIGHT REASONABLY IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. | |
| FORM 990, PART VI, SECTION B, LINE 15 | ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING 3 ELEMENTS: 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CONTROLLER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION ARRANGEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. | |
| FORM 990, PART VI, SECTION C, LINE 19 | THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDTAION'S WEBSITE. | |
| CHANGES IN NET ASSETS OR FUND BALANCES: | FORM 990, PART XI, LINE 5: | NET UNREALIZED GAINS ON INVESTMENTS: 461,145. |
| PROGRAM DESCRIPTIONS | FORM 990, PART II, LINES 4A AND 4B | THE NATIONAL FOUNDATION FOR CANCER RESEARCH (NFCR) IS A LEADING PUBLIC CHARITY DEDICATED TO FUNDING CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO CANCER PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND, ULTIMATELY, CURES FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. SINCE 1973, NFCR HAS PROVIDED OVER $288 MILLION IN SUPPORT OF DISCOVERY-ORIENTED CANCER RESEARCH FOCUSED ON UNDERSTANDING HOW AND WHY CELLS BECOME CANCEROUS, AND ON PUBLIC EDUCATION RELATING TO CANCER PREVENTION, DETECTION, AND TREATMENT. NFCR'S SCIENTISTS ARE DISCOVERING CANCER'S MOLECULAR MYSTERIES AND TRANSLATING THEIR DISCOVERIES INTO THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR IS ABOUT RESEARCH FOR A CURE-CURES FOR ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG. SUMMARY OF RESEARCH ACCOMPLISHMENTS THIS YEAR, NFCR-FUNDED SCIENTISTS MADE SIGNIFICANT DISCOVERIES THAT WILL HAVE A LASTING INFLUENCE ON CANCER RESEARCH AND SAVE MANY LIVES DOWN THE ROAD. BELOW IS A SUMMARY OF SELECT SCIENTIFIC ACCOMPLISHMENTS IN 2010: DEVELOPMENT AND OPTIMIZATION OF 25 NOVEL RESEARCH TOOLS AND TECHNOLOGIES. PROGRESS IN THIS AREA IS CRITICAL FOR IMPROVING ANTI-CANCER DRUG SCREENING, BRINGING NEW DRUGS TO THE MARKETPLACE, AND IMPROVING CANCER TREATMENTS. IDENTIFICATION OF 30 NEW DRUG CANDIDATES. ALL OF THESE ANTICANCER AGENTS HAVE THE POTENTIAL TO BECOME, AND SOME WILL BECOME, EFFECTIVE TREATMENT OPTIONS, IMPROVING ON ANYTHING CURRENTLY AVAILABLE. THESE POTENTIAL CANCER THERAPEUTICS WILL BE FURTHER EVALUATED AND DEVELOPED IN THE COMING YEAR. IDENTIFICATION AND CHARACTERIZATION OF 11 CANCER BIOMARKERS. FURTHER DEVELOPMENT OF THESE CHARACTERISTIC MOLECULES IS CRUCIAL FOR EARLY DIAGNOSIS AND PERSONALIZED TREATMENT. 12 CLINICAL TRIALS CONDUCTED TO ADVANCE NEW DRUGS OR NEW TREATMENTS FROM THE LABORATORY RESEARCH PHASE INTO CLINICAL DEVELOPMENT. IDENTIFICATION AND EVALUATION OF 3 DIETARY NUTRIENTS THAT MAY HAVE POTENTIAL THERAPEUTIC PROPERTIES FOR USE IN CANCER PREVENTION AND TREATMENT. PUBLISHED MORE THAN 124 RESEARCH PAPERS IN INTERNATIONAL, PEER-REVIEWED SCIENCE JOURNALS THAT HAVE MADE SIGNIFICANT CONTRIBUTIONS TO OUR UNDERSTANDING OF THE COMPLEX NATURE OF CANCER. HIGHLIGHTS OF NFCR-FUNDED CANCER RESEARCH AND PUBLIC EDUCATION INITIATIVES IN 2010 IN LABORATORIES ACROSS THE UNITED STATES, EUROPE, AND CHINA, NFCR SCIENTISTS AND THEIR RESEARCH TEAMS ARE WORKING AT THE CUTTING-EDGE OF CANCER RESEARCH TODAY. HIGHLIGHTED HERE IS A SAMPLING OF THE IMPORTANT RESEARCH BREAKTHROUGHS IN CANCER PREVENTION, DETECTION, AND TREATMENT, AND THE COMPLEMENTARY PUBLIC EDUCATION CAMPAIGNS THAT INFORM THE PUBLIC ABOUT THESE LIFE-SAVING DISCOVERIES. CANCER PREVENTION STOPPING CANCER BEFORE IT STARTS IS THE BEST WAY TO HELP FAMILIES AROUND THE WORLD FROM HEARING THOSE THREE DEVASTATING WORDS, "YOU HAVE CANCER." BECAUSE AN ESTIMATED ONE-THIRD OF ALL CANCERS CAN BE PREVENTED, NFCR IS WORKING AROUND THE CLOCK TO RESEARCH HOW CANCER STARTS IN THE FIRST PLACE, SO THAT WE CAN PUT A STOP TO IT. BELOW ARE SOME HIGHLIGHTS OF NFCR RESEARCH ON CANCER PREVENTION. DEVELOPING NEW DRUGS TO PREVENT PANCREATIC CANCER. VERY FEW PANCREATIC CANCER PATIENTS LIVE FIVE YEARS FOLLOWING THEIR INITIAL DIAGNOSIS. CONSIDERED TO BE "THE FATHER OF CHEMOPREVENTION" FOR HIS PIONEERING USE OF DRUGS THAT FEND OFF CANCER AND OTHER DISEASES, MICHAEL SPORN, M.D., AT DARTMOUTH MEDICAL SCHOOL (NEW HAMPSHIRE) BELIEVES THAT CHEMOPREVENTION IS THE BEST AND MOST PRACTICAL WAY TO MEET THIS CHALLENGE OF PANCREATIC CANCER. HIS TEAM HAS NOW DEMONSTRATED THAT THEIR SYNTHETIC TRITERPENOIDS DRUGS HAVE PREVENTATIVE EFFECTS AGAINST PANCREATIC CANCER FORMATION IN A COMPLEX MODEL. BECAUSE THE SAME GENETIC DEFECTS IN THE MODEL ARE ALSO FOUND IN MANY PANCREATIC CANCER PATIENTS, WITH CONTINUED SUCCESS, THESE TRITERPENOIDS CAN RAPIDLY ENTER CLINICAL TRIALS FOR TREATING INDIVIDUALS AT HIGH RISK OF DEVELOPING PANCREATIC CANCER. DISCOVERING NATURAL PRODUCTS THAT MAY PREVENT SKIN CANCER. DR. HELMUT SIES (GERMANY) RECENTLY DEMONSTRATED THAT CERTAIN MARINE FISH HAVE A SUPERIOR ANTI-OXIDATIVE COMPOUND THAT PROTECTS SKIN CELLS FROM THE OXIDATIVE DAMAGES PRODUCED BY EXPOSURE TO UV LIGHT. OXIDATION-THE DAMAGE TO CELLS BY FREE RADICAL COMPOUNDS-IS THE LARGEST ENVIRONMENTAL CAUSE OF CANCER. DR. SIES IS WELL-RECOGNIZED FOR HIS RESEARCH ON THE CANCER PREVENTION EFFECTS OF LYCOPENE, THE ANTIOXIDANT FOUND IN TOMATOES AND CARROTS. AS A WORLD-RENOWNED BIOCHEMIST AND NATURAL PRODUCTS EXPERT, DR. SIES' FINDINGS CONTINUOUSLY ENHANCE PUBLIC AWARENESS OF MAINTAINING A HEALTHY DIET FOR CANCER PREVENTION. INVESTIGATING DIETARY SELENIUM AND COLORECTAL CANCER-PREVENTION. THE DIETARY MICRONUTRIENT, SELENIUM, IS INCORPORATED INTO SELENOPROTEINS THAT HAVE ANTI-OXIDATIVE FUNCTIONS TO KEEP OUR BODIES HEALTHY. DIETARY SELENIUM HAS BEEN SHOWN TO HAVE A BENEFICIAL IMPACT IN CLINICAL STUDIES FOR PREVENTION AND THERAPY OF COLORECTAL CANCER. HOWEVER, THE MOLECULAR BASIS FOR ITS EFFECTS IS NOT CLEARLY UNDERSTOOD. DR. HELMUT SIES (GERMANY), A WORLD-RENOWNED EXPERT ON CANCER-PREVENTIVE EFFECTS OF MICRONUTRIENTS, IS RESEARCHING A ROLE OF THE ANTI-OXIDANT SELENOPROTEINS IN THE PROGRESSION OF INFLAMMATORY BOWEL DISEASE (IBD) TO COLORECTAL CANCER. IN TUMOR MODELS OF IBD, HE IDENTIFIED INFLAMMATORY MOLECULES THAT DECREASED THE SYNTHESIS OF SELENOPROTEINS. A REDUCTION IN LEVELS OF SELENOPROTEINS MAY DIMINISH THE TOTAL ANT-OXIDANT CAPACITY OF THE INTESTINAL CELLS, ALLOWING IBD TO PROGRESS TO COLORECTAL CANCER. DR. SIES' IMPORTANT FINDINGS ARE LAYING THE GROUNDWORK FOR THE MOLECULAR BASIS OF HOW SELENIUM AND SELENOPROTEINS MAY PLAY A ROLE IN PREVENTING THIS FORM OF COLORECTAL CANCER. PREDICTING THE DEVELOPMENT OF SMOKING-RELATED LUNG CANCER IN HIGH-RISK PATIENTS. WAUN KI HONG, M.D., M.D. ANDERSON CANCER CENTER (TEXAS) IS A WORLD RENOWNED CANCER RESEARCHER ON THE ROLE OF SMOKING ON LUNG CANCER DEVELOPMENT. DR. HONG IS LEADING HIS TEAM IN BUILDING "RISK PREDICTION MODELS" FROM RESULTS OF THEIR CLINICAL TRIALS AND COLLECTIVE RESEARCH WHICH INCLUDES IDENTIFYING PROGNOSTIC BIOMARKERS, GENETIC VARIATIONS THAT MAY INDICATE PATIENTS AT RISK FOR LUNG CANCER RECURRENCE, AND CHEMOPREVENTION AGENTS. THE RESEARCH HAS IDENTIFIED 21 (TWENTY-ONE) BIOMARKERS THAT IS LEADING TO AN UNDERSTANDING OF TUMOR DEVELOPMENT IN SMOKING-RELATED LUNG CANCER. THE RESULTS OF THEIR ONGOING ANALYSIS WILL SERVE AS THE FOUNDATION FOR THE NEXT PHASE, A PROGRAM ON CHEMOPREVENTION IN LUNG CANCER. DR. HONG ENVISIONS THAT CLINICIANS MAY SOON BE ABLE TO PROVIDE PERSONALIZED CHEMOPREVENTION PROGRAMS FOR THE BEST CARE FOR SMOKERS OR PREVIOUS SMOKERS WHO ARE AT HIGH RISK TO DEVELOP LUNG CANCER OR FOR THEIR CANCER TO RETURN. ADDITIONAL RESEARCH ON CANCER PREVENTION INCLUDES: INVESTIGATING THE CANCER PREVENTION EFFECTS OF DNA INTERCALATING AGENTS. JANOS LADIK, PH.D., UNIVERSITY ERLANGEN-NURNBERG (GERMANY). IN ADDITION TO FUNDING LIFE-SAVING CANCER PREVENTION RESEARCH, NFCR IS ALSO COMMITTED TO INFORMING THE PUBLIC ABOUT MAKING HEALTHY LIFESTYLE CHOICES THAT CAN HELP SAVE SOMEONE FROM GOING THROUGH THE ORDEAL OF CANCER - CHOICES WHICH MAY HELP SAVE A LIFE. HEALTHY RECIPES: ONE OF THE MOST IMPORTANT FACTORS IN A HEALTHY LIFESTYLE IS DIET. FOR YEARS, NFCR HAS BEEN PROVIDING HEALTHY RECIPES EACH MONTH TO VISITORS TO OUR WEBSITE, WWW.NFCR.ORG, AND SUBSCRIBERS TO OUR E-NEWSLETTER. NFCR HAS AMASSED A COLLECTION OF OVER 200 HEALTHY RECIPES, WHICH ARE DISTRIBUTED TO OVER 35,000 PEOPLE EACH MONTH. ON YOUR HEALTH SERIES: NFCR CONTINUALLY WRITES AND POSTS ARTICLES RELATING TO UPDATES IN CANCER PREVENTION, WITH TITLES SUCH AS TEA: THE LATEST WEAPON AGAINST CANCER, SEEK SHADE NOT SUN, WHAT HAPPENS WHEN YOU SMOKE A CIGARETTE, AND WEIGH LESS, LIVE LONGER. THESE ARTICLES WERE BEEN READ OVER 177,000 TIMES IN 2009. ON YOUR HEALTH NOTE CARDS: ARTISTICALLY DESIGNED NOTE CARDS ENCOURAGE NFCR DONORS TO STAY IN TOUCH WITH THEIR FAMILIES AND FRIENDS WHILE SHOWING SUPPORT FOR NFCR'S LIFE-SAVING CANCER RESEARCH PROGRAMS. CANCER PREVENTION PRESS RELEASES: NFCR PROVIDES UP-TO-DATE NEWSFLASHES ABOUT WHAT CAN BE DONE TO BE BETTER PROTECTED AGAINST CANCER. THESE PUBLIC EDUCATION PRESS RELEASES HAVE RECEIVED OVER 20 MILLION IMPRESSIONS. NEWSLETTER: OUR COMPREHENSIVE RESEARCH FOR A CURE NEWSLETTER INCLUDES IN-DEPTH INFORMATION ABOUT VARIOUS METHODS OF CANCER PREVENTION. EACH ISSUE IS SENT TO OVER 125,000 PEOPLE. E-NEWSLETTER: THE MONTHLY ELECTRONIC NEWSLETTER RESEARCH FOR A CURE INCLUDES USEFUL REMINDERS ABOUT CANCER PREVENTION TIPS, AND IS SENT TO OVER 35,000 PEOPLE EACH MONTH. INSERTS IN OUR DIRECT MAIL PACKAGES: NFCR MAILINGS INCLUDE SEASONAL HEALTHY EATING RECIPES AND THE NUTRITIONAL BENEFITS OF DIFFERENT FRUITS AND VEGETABLES, AND OTHER PREVENTION TIPS. |
| CANCER DETECTION FOR MANY TYPES OF CANCER, EARLY DETECTION IS KEY. IF THE CANCER CAN BE REMOVED AND TREATED BEFORE IT SPREADS, OR METASTASIZES, THE PATIENT HAS A MUCH BETTER CHANCE AT LIVING A LONGER, CANCER-FREE LIFE. THAT'S WHY NFCR SCIENTISTS ARE WORKING ON NEW AND MORE EFFECTIVE WAYS TO DETECT CANCER EARLIER. BELOW ARE SOME HIGHLIGHTS OF OUR RESEARCH ON CANCER DETECTION. TRACKING CANCER IN REAL-TIME WITH A BREAKTHROUGH TECHNOLOGY. DANIEL A. HABER, M.D., PH.D., AT MASSACHUSETTS GENERAL HOSPITAL, BOSTON, MA, AND HIS TEAM OF SCIENTISTS HAVE DEVELOPED A REVOLUTIONARY WAY TO DETECT AND CAPTURE CIRCULATING TUMOR CELLS (CTCS) IN THE BLOOD. THIS TECHNOLOGY MAY PROVIDE DOCTORS WITH AN UNPRECEDENTED MEANS OF RAPIDLY DETECTING INVASIVE CANCERS BY USING AN EASY TO ADMINISTER BLOOD TEST. KNOWING ABOUT THE PRESENCE AND THE GENETIC FEATURES OF CANCER CELLS IN A PATIENT'S BLOOD MAY ENABLE THE PHYSICIAN TO IDENTIFY AND PRESCRIBE TARGETED ANTI-CANCER TREATMENTS EARLY ON, BEFORE THE DISEASE CAN SPREAD AND THEN RESIDE IN ANOTHER ORGAN. SUCH A TEST COULD ALSO ENABLE DOCTORS TO MONITOR THE EFFECTIVENESS OF THEIR PATIENT'S TREATMENT AND MAKE ANY NECESSARY TREATMENT CHANGES, INCREASING THE POSITIVE EFFECT OF ALL CANCER THERAPIES. ADVANCEMENTS IN IMAGING TECHNOLOGIES TO DETECT EARLY CHANGES IN CANCER CELLS. JAMES BASILION, PH.D., AND HIS COLLEAGUES AT THE NFCR CENTER FOR MOLECULAR IMAGING (OHIO) ARE ESTABLISHING A NEW TECHNOLOGY PLATFORM - MOLECULAR IMAGING FOR EARLY DETECTION AND IMPROVED TREATMENT OF CANCER. HIGHLY SENSITIVE IMAGING TOOLS ARE BEING DEVELOPED THAT CAN DETECT MULTIPLE MOLECULAR MARKERS SPECIFIC TO CANCERS SUCH AS BREAST, PROSTATE, AND BRAIN CANCER. UTILIZING AN ENTIRELY NEW TECHNIQUE THAT PERMITS THE SIMULTANEOUS IMAGING OF MULTIPLE MOLECULAR MARKERS, SCIENTISTS IN THIS CENTER MAKE IT POSSIBLE TO IDENTIFY CANCER AT A VERY EARLY AND MORE TREATABLE STAGE, SIGNIFICANTLY IMPROVING PATIENTS' CHANCES OF SURVIVAL. BLOOD BIOMARKERS FOR PREDICTING PROGNOSIS OF COLORECTAL CANCER. WEI ZHANG, PH.D., AT MD ANDERSON CANCER CENTER, HOUSTON, TX, IS CONDUCTING AN IN-DEPTH INVESTIGATION OF SMALL PIECES OF RNA (MICRORNAS) THAT ARE DETECTED IN THE BLOOD THAT MAY SERVE AS BIOMARKERS FOR COLORECTAL CANCER. USING BLOOD SAMPLES FROM HEALTHY DONORS AND PATIENTS WITH STAGE I THROUGH IV COLORECTAL CANCER, DR. ZHANG AND HIS TEAM HAVE DETERMINED ONE MICRORNA THAT MAY PREDICT PROGNOSIS FOR STAGE IV COLORECTAL CANCER PATIENTS. MOREOVER, THE MICRORNA WAS FOUND IN BLOOD SAMPLES OF PATIENTS FROM TWO ETHNIC POPULATIONS, STRENGTHENING ITS VALIDITY AS A BIOMARKER. MICRORNAS MAY REPRESENT A KEY ADVANCEMENT IN THE SEARCH FOR VALUABLE BLOOD BIOMARKERS FOR COLON CANCER THAT MAY BE TRANSLATED INTO CLINICAL APPLICATIONS INCLUDING PROGNOSIS, MONITORING RESPONSE TO THERAPY, AND DETECTING DISEASE RECURRENCE TO SAVE PATIENTS' LIVES. ADDITIONAL RESEARCH ON CANCER DETECTION INCLUDES: SUCCESSFUL DEVELOPMENT OF NEW HIGH THROUGHPUT PROTEIN ARRAY DETECTION METHOD TO IDENTIFY PATIENTS WITH EARLY STAGE CANCER. LAWRENCE MARNETT, PH.D., DANIEL LIEBLER, PH.D., RICHARD CAPRIOLI, PH.D, VANDERBILT UNIVERSITY (TENNESSEE) DEVELOPMENT OF INHIBITORS OF A GENE HIGHLY RELATED TO INITIATION AND PROGRESSION OF PANCREATIC AND LIVER CANCER. DANIEL VON HOFF, M.D., LAURENCE HURLEY, PH.D., TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (ARIZONA) IN ADDITION TO OUR FOCUS ON RESEARCH, THE NFCR TEAM IS COMMITTED TO KEEPING THE PUBLIC UP-TO-SPEED ON CANCER SCREENINGS AND DIAGNOSTIC TESTS THAT CAN GREATLY INCREASE THE CHANCES OF CATCHING CANCER EARLY. EARLY CANCER DETECTION CHARTS: A DETAILED LIST OF 22 OF THE MOST COMMON CANCERS, THIS CHART CONTAINS INFORMATION ABOUT EACH CANCER'S SIGNS AND SYMPTOMS, AS WELL AS DIAGNOSTIC AIDES. THIS IS OUR MOST REQUESTED PUBLICATION. CHILDHOOD DETECTION CANCER CHART: PROVIDES CONCISE AND COMPREHENSIVE EARLY WARNING SIGNS OF CHILDHOOD CANCERS TO HELP PARENTS RECOGNIZE SYMPTOMS AND BEHAVIORS ASSOCIATED WITH DIFFERENT TYPES OF CHILDHOOD CANCER. THIS PUBLICATION WAS FUNDED BY A GRANT FROM THE LUDCKE FOUNDATION OF BOSTON, MASSACHUSETTS AND HAS BEEN DISTRIBUTED TO OVER 200,000 FAMILIES. SCREENING TOOLS: NFCR OFFERS INFORMATION ON SCREENING TOOLS - CERTAIN EXAMINATIONS OR TESTS IN PEOPLE WHO DO NOT HAVE ANY SYMPTOMS OF CANCER, BUT ARE AT HIGH RISK FOR DEVELOPING CERTAIN TYPES OF CANCER. THIS INCLUDES INFORMATION ON GENETIC TESTING, PLUS SPECIFIC SCREENING INFORMATION FOR BREAST, CERVICAL, COLON, LUNG, OVARIAN, PROSTATE, AND UTERINE CANCER. DIAGNOSTIC AND MONITORING TESTS. NFCR OFFERS INFORMATION ON DIAGNOSTIC TESTS, WHICH DIAGNOSE AND MONITOR CANCER PROGRESSION. THIS INCLUDES INFORMATION ON PATHOLOGY TESTS, DIAGNOSTIC IMAGING, BLOOD TESTS, TUMOR MARKERS, AND GENOMICS. CANCER TREATMENT IT'S EXTREMELY SATISFYING TO MAKE A RESEARCH DISCOVERY; BUT THE MOST SATISFYING IS TO KNOW THAT OUR RESEARCH DISCOVERIES ARE HELPING PEOPLE AROUND THE WORLD. TRANSLATING BREAKTHROUGHS IN THE LABORATORY INTO LIFE-SAVING TREATMENTS IS MAKING A DIFFERENCE - TO CANCER PATIENTS AND TO THE PEOPLE WHO LOVE THEM. INNOVATIVE GENE THERAPY FOR METASTATIC PROSTATE CANCER. NFCR SCIENTIST PAUL B. FISHER, M.PH., PH.D., AT VIRGINIA COMMONWEALTH UNIVERSITY IN RICHMOND, VIRGINIA, HAS DEVELOPED A POTENTIAL TARGETED CANCER THERAPY FROM A GENETICALLY REPROGRAMMED VIRUS CALLED "CANCER TERMINATOR VIRUS" (CTV). A SPECIAL GENE ELEMENT DISCOVERED BY DR. FISHER IS INCORPORATED IN CTV AND ALLOWS IT TO TARGET AND REPLICATE ONLY IN TUMOR CELLS, AN EFFECT THAT WOULD ALLEVIATE ANY DANGEROUS SIDE EFFECTS FROM KILLING HEALTHY CELLS, LIKE THOSE EFFECTS PRODUCED BY STANDARD CYTOTOXIC THERAPIES. CTV ALSO DELIVERS THE GENE FOR INTERFERON GAMMA (IFN?), OUR BODY'S IMMUNE MODULATING MOLECULE THAT WILL DIRECTLY ELICIT AN IMMUNE RESPONSE IN THE TUMOR AND ENERGIZE THE IMMUNE SYSTEM TO SEEK AND DESTROY ANY CANCER CELLS, INCLUDING THOSE THAT HAVE METASTASIZED. CTV WILL BE ESPECIALLY USEFUL FOR REFRACTORY PROSTATE CANCER PATIENTS WHOSE TUMORS HAVE STOPPED RESPONDING TO OTHER TREATMENTS, AND FOR THOSE WHOSE CANCER HAS METASTASIZED. PERSONALIZED MEDICINE FOR NON-SMALL CELL LUNG CANCER PATIENTS. WAUN KI HONG, M.D., AT MD ANDERSON CANCER CENTER, HOUSTON, TX, IS A WORLD-RENOWNED RESEARCHER WHO INITIATED THE BATTLE PROGRAM, OR BIOMARKER-BASED APPROACHES OF TARGETED THERAPY FOR LUNG CANCER ELIMINATION TO DEVELOP INDIVIDUALIZED TARGETED THERAPIES FOR PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) THAT IS RESISTANT TO CHEMOTHERAPY. RECENTLY, DR. HONG'S TEAM PRESENTED VERY ENCOURAGING RESULTS OF FOUR (4) CLINICAL TRIALS THAT TESTED PERSONALIZED MEDICINE PROTOCOLS IN LUNG CANCER PATIENTS. IN THESE TRIALS, PATIENTS WERE ASSIGNED TO THE TREATMENT DRUG WHICH THEY WERE MOST LIKELY TO RESPOND BASED ON THEIR PERSONAL BIOMARKER PROFILE IDENTIFIED THROUGH TUMOR BIOPSIES. BATTLE IS AN IMPORTANT STEP TOWARD PERSONALIZED MEDICINE AND MARKS A PARADIGM SHIFT FOR CLINICAL TRIALS BY DEMONSTRATING THE FEASIBILITY OF A BIOPSY-BASED, BIOMARKER TRIAL. THESE INITIATIVES WILL MOVE PERSONALIZED MEDICINE FORWARD AND IMPROVE TREATMENT EFFICACY TO INDIVIDUAL PATIENTS. ANTI-ANGIOGENESIS: SHUTTING DOWN CANCER. PAUL SCHIMMEL, PH.D., AND COLLEAGUES AT THE SCRIPPS RESEARCH INSTITUTE, LA JOLLA, CA, ARE SEEKING TO UNDERSTAND WHY HUMAN AMINO ACYL TRNA SYNTHETASES, ONE OF THE ESSENTIAL ENZYMES OF PROTEIN SYNTHESIS MACHINERY FOUND IN ALL ORGANISMS, HAVE DISTINCT ADDITIONAL VITAL ACTIVITIES, THAT ARE INVOLVED IN PATHWAYS RELEVANT TO TREATING CANCER AND OTHER DISEASES. IN THE PAST YEAR, THE SCIENTISTS PUBLISHED A LANDMARK PAPER ON THEIR DISCOVERY OF HOW ONE TRNA SYNTHETASE INHIBITS BLOOD VESSEL FORMATION, POTENTIALLY FUELING DEVELOPMENT OF NEW ANTI-ANGIOGENESIS TREATMENTS WHICH HAVE BEEN SO EFFECTIVE IN KEEPING CANCER FROM GROWING AND SPREADING. NEW ANTIBODIES THAT TARGET KIDNEY CANCER OPENS DOOR FOR NOVEL THERAPY. WAYNE MARASCO, M.D., PH.D., AT THE DANA-FARBER CANCER INSTITUTE, HARVARD MEDICAL SCHOOL, CAMBRIDGE, MA, IS DISCOVERING AND ENGINEERING THERAPEUTIC ANTIBODIES FOR CANCER RESEARCH AND CLINICAL APPLICATIONS. PREVIOUS RESEARCH ESTABLISHED A LIBRARY CONTAINING 1.6 BILLION DIFFERENT HUMAN SFV ANTIBODY-DISPLAYING PHAGES, A TREMENDOUS RESOURCE FOR DEVELOPING MONOCLONAL ANTIBODY-BASED TARGETED THERAPIES. IN THE PAST YEAR, HE HAS LED HIS TEAM TO IDENTIFY HIGH AFFINITY HUMAN SFV ANTIBODIES AGAINST A UNIQUE DOMAIN OF A SELECTED CANCER TARGET FOR RENAL CELL CARCINOMA. THESE REAGENTS HOLD PROMISE FOR NEW IMMUNOTHERAPIES AND DIAGNOSTIC TOOLS FOR KIDNEY CANCER PATIENTS. DISCOVERING NEW BIOMARKERS AND THERAPIES: STOPPING FORMATION OF BLOOD VESSELS THAT SUPPORT GROWTH OF ALL TYPES OF TUMORS . HAROLD DVORAK, M.D. BETH ISRAEL DEACONESS MEDICAL CENTER, HARVARD MEDICAL SCHOOL (MASSACHUSETTS) NEW STRATEGIES TO OVERCOME DRUG RESISTANCE TO TAXOL FOR BREAST CANCER PATIENTS. SUSAN BAND HORWITZ, PH.D., ALBERT EINSTEIN COLLEGE OF MEDICINE (NEW YORK) | ||
| NEW STRATEGIES TO OVERCOME DRUG RESISTANCE TO TAXOL FOR BREAST CANCER PATIENTS. SUSAN BAND HORWITZ, PH.D., ALBERT EINSTEIN COLLEGE OF MEDICINE (NEW YORK) NEWLY DISCOVERED ANTI-VIRAL COMPOUNDS AND NATURAL PRODUCTS THAT HAVE ANTICANCER ACTIVITY IN LIVER CANCER. YUNG-CHI CHENG, M.D., YALE UNIVERSITY (CONNECTICUT) ADVANCES IN THE WORLD'S LARGEST COMPUTATIONAL DRUG SCREENING TECHNOLOGY FOR ACCELERATED IDENTIFICATION OF NEW CANCER DRUGS. W. GRAHAM RICHARDS, D.SC., UNIVERSITY OF OXFORD (UNITED KINGDOM) DEVELOPING NEW TREATMENT FOR ACUTE MYELOID LEUKEMIA (AML). CURT CIVIN, M.D., UNIVERSITY OF MARYLAND, BALTIMORE. TUMOR-TARGETING IMMUNOTHERAPY FOR LYMPHOMA. LAURENCE COOPER, M.D., PH.D., M.D. ANDERSON CANCER CENTER (TEXAS) NEW DRUG INTERVENTIONS FOR SOFT TISSUE SARCOMAS. DINA LEV, M. D., MD ANDERSON CANCER CENTER (TEXAS) DEVELOPMENT OF INHIBITORS OF A CANCER PATHWAY THAT SENSITIZE PANCREATIC CANCER TO TARGETED THERAPY- A NEW COMBINATION TREATMENT. . DANIEL VON HOFF, M.D., TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (ARIZONA) DISSECTING MOLECULAR CHANGES INVOLVED IN METASTASIS OF SKIN CANCER: DEVELOPING THERAPIES TO STOP THE LETHAL SPREAD. DANNY WELCH, PH.D., UNIVERSITY OF ALABAMA IDENTIFYING MARKERS TO PREDICT THE EFFECT OF ANTI-ANGIOGENIC THERAPY FOR BRAIN CANCER PATIENTS. RAKESH JAIN, PH.D., MASSACHUSETTS GENERAL HOSPITAL IMPROVING TREATMENT OPTIONS FOR CANCER PATIENTS IS JUST ONE STEP IN THE JOURNEY. IT IS ALSO IMPORTANT TO HELP EDUCATE PATIENTS AND ONCOLOGISTS ABOUT THE LATEST TREATMENT OPTIONS MADE POSSIBLE THROUGH RESEARCH. BELOW ARE JUST SOME OF THE WAYS THAT NFCR IS SERVING COMMUNITIES BY SHARING THE LATEST NEWS IN CANCER TREATMENT. TREATMENT DECISION TOOLS: IN PARTNERSHIP WITH US ONCOLOGY, NFCR OFFERS FREE ONLINE TREATMENT DECISION TOOLS AT WWW.NFCR.ORG/PATIENTSUPPORT TO HELP CANCER PATIENTS MAKE MORE EDUCATED DECISIONS WITH THEIR PHYSICIANS. HIGHLY RECOGNIZED ONCOLOGISTS MATRIX: THIS RESOURCE PROVIDES NFCR DONORS AND FAMILIES A LIST OF NFCR-RECOMMENDED ONCOLOGISTS IN THE U.S. SO THAT THEY CAN ACCESS THE BEST ADVANCED CANCER CARE AVAILABLE. TYPES OF TREATMENT. NFCR OFFERS INFORMATION ON DIFFERENT TYPES OF TREATMENT, INCLUDING CHEMOTHERAPY, RADIATION THERAPY, SURGERY, HORMONAL THERAPY, TARGETED THERAPY, COMPLEMENTARY & ALTERNATIVE THERAPY, AND THE SIDE EFFECTS OF TREATMENT. CLINICAL TRIALS. NFCR OFFERS INFORMATION ON CLINICAL TRIALS, INCLUDING PHASES OF CLINICAL TRIALS, CLINICAL TRIAL SAFEGUARDS, THE COST OF CLINICAL TRIALS, AND FINDING SPECIFIC CLINICAL TRIALS. CANCER HEADLINES. NFCR TRACKS AND PUBLISHES THE LATEST IN CANCER HEADLINES TO EDUCATE THE PUBLIC ABOUT UP-AND-COMING TREATMENTS. NFCR FUNDED RESEARCHERS IN 2010 NFCR HAS BUILT A SCIENCE PROGRAM THAT NOW INVOLVES NEARLY 50 TOP RESEARCH LABORATORIES IN THE U.S. AND OTHER COUNTRIES AROUND THE WORLD. TO MAXIMIZE THE VALUE OF OUR RESOURCES AND WORK MORE EFFICIENTLY, NFCR ORGANIZES ITS SCIENCE PROGRAM USING THREE DIFFERENT FUNDING STRUCTURES, NAMELY THE NFCR RESEARCH DISCOVERY CENTERS, NFCR FELLOWS, AND NFCR PROJECT DIRECTORS. NFCR RESEARCH DISCOVERY CENTERS ARE THE CORE OF OUR RESEARCH NETWORK. THEY PROVIDE THE PLATFORM FOR COLLABORATION. NFCR HAS ESTABLISHED EIGHT CENTERS EQUIPPED WITH CUTTING-EDGE TECHNOLOGIES AND EACH WITH THEIR OWN FOCUS ON ONE OR MORE OF THE MOST CRITICAL RESEARCH FRONTS. BELOW IS THE LIST OF THE NFCR CENTERS AND EACH OF THEIR DIRECTORS, WHO ARE ONE OR MORE HIGHLY ACCOMPLISHED CANCER RESEARCH LEADERS. NFCR FELLOWS ARE DISTINGUISHED AND WELL-ESTABLISHED SCIENTISTS WHO HAVE EXCELLENT TRACK RECORDS IN THEIR FIELDS OF SCIENTIFIC INTEREST. NFCR PROVIDES THEM WITH MULTIPLE YEARS OF UNRESTRICTED FUNDING TO ALLOW THE NURTURING OF THEIR DISCOVERY-ORIENTED RESEARCH. NFCR PROJECT DIRECTORS ARE OUTSTANDING RESEARCHERS WHO ARE TAKING RISKS TO EXPLORE NEW RESEARCH FIELDS. NFCR PROVIDES "SEED FUNDING" TO THEIR PROJECT-BASED RESEARCH, PROVIDING THEM A PRECIOUS OPPORTUNITY TO VALIDATE THEIR INNOVATIVE IDEAS AND MOVE PROMISING RESEARCH FORWARD. NFCR IS ABOUT SAVING LIVES THE FINANCIAL SUPPORT OF 4 MILLION DONORS TO NFCR IS PAYING OFF. MORE INDIVIDUALS DIAGNOSED WITH CANCER ARE SURVIVING TODAY THAN EVER BEFORE, AND THOSE WHO UNFORTUNATELY DO NOT SURVIVE LIVE LONGER AND EXPERIENCE A MUCH BETTER QUALITY OF LIFE THAN WAS POSSIBLE JUST A FEW YEARS AGO. EVERY DAY AT NFCR, OUR RESEARCHERS REPORT PROGRESS IN DEVELOPING PROMISING NEW TREATMENTS FOR CANCER. BUT UNTIL THERE IS A CURE, WE WILL NOT BE SATISFIED-TOO MANY LIVES ARE AT STAKE. NFCR IS COMMITTED TO FUNDING RESEARCH BECAUSE WE WANT TO CURE CANCER. WE CONTINUE TO PURSUE EVERY QUALIFIED LEAD AND EVERY OPPORTUNITY THAT MERITS FUNDING WITH THE RESOURCES WE HAVE AVAILABLE. AS AN ORGANIZATION THAT RELIES SOLELY ON THE GENEROSITY OF MILLIONS OF DONORS NATIONWIDE, WE TAKE THE FIGHT AGAINST CANCER VERY SERIOUSLY. NO RISK IS TOO GREAT WHEN IT COMES TO SAVING LIVES! ADDITIONAL INFORMATION ABOUT THE NATIONAL FOUNDATION FOR CANCER RESEARCH CAN BE FOUND AT WWW.NFCR.ORG OR BY CALLING (800) 321-CURE (2873). |
| Software ID: | |
| Software Version: |